Kintara Therapeutics, Inc. Stock Price, News & Analysis

Kintara Therapeutics (Nasdaq: KTRA), a biopharmaceutical firm specializing in cancer therapies, announced CEO Saiid Zarrabian's participation in the Benzinga Global Small Cap Conference on May 14, 2021, presenting at 12:25 PM ET. Investors can schedule one-on-one meetings post-conference. Kintara is developing two Phase 3-ready treatments: VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer, with REM-001 showing an 80% complete response rate in prior trials.

Kintara Therapeutics (Nasdaq: KTRA) announced the appointment of Tamara A. Seymour to its Board of Directors, replacing John Liatos, who remains as Senior VP of Business Development. Seymour, a seasoned finance executive with over 30 years in biotech, has successfully raised over $250 million in equity and debt financing. Under her leadership, Kintara progresses its cancer therapies, VAL-083 and REM-001, targeting glioblastoma and metastatic breast cancer, respectively. The Company aims to address significant unmet medical needs in oncology.

Kintara Therapeutics (Nasdaq: KTRA) presented interim data from two Phase 2 trials of VAL-083 for glioblastoma multiforme (GBM) at the AACR Annual Meeting on April 12, 2021. The results show promising median progression-free survival (PFS) of 10.0 months in newly-diagnosed patients and 7.9 months in recurrent patients, outperforming historical controls. Both trials, conducted in Texas and China, have informed the upcoming GBM AGILE study. The most common adverse effect remains myelosuppression, with a few serious adverse events reported.

Kintara Therapeutics (Nasdaq: KTRA) announced that CEO Saiid Zarrabian will speak at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 9:45 am ET. Investors can access a corporate presentation after registering for the event. Kintara focuses on developing innovative cancer therapies, including VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. Both drugs are entering late-stage clinical trials, showcasing strong clinical efficacy and safety profiles.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) announced that CEO Saiid Zarrabian will participate in Maxim Group's 2021 Emerging Growth Virtual Conference on March 17-18, 2021. Zarrabian will speak on glioblastoma treatments at 9:30 am ET, with an archived replay available later. Kintara is focused on developing therapies for rare cancers, with two Phase 3-ready projects: VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. VAL-083 has shown clinical activity in various cancers, while REM-001 has an 80% complete response rate in previous studies.

Kintara Therapeutics (Nasdaq: KTRA) appointed Dr. Mario Lacouture to its REM-001 Scientific Advisory Board, focusing on Cutaneous Metastatic Breast Cancer (CMBC) as they prepare for late-stage pivotal testing of their photodynamic therapy platform, REM-001. Dr. Lacouture, a leading expert at Memorial Sloan Kettering Cancer Center, brings extensive experience in dermatologic care for cancer patients. Kintara is also advancing its VAL-083 therapy for glioblastoma multiforme (GBM) while pursuing approval for REM-001, which has shown an 80% complete response rate in previous trials.

Kintara Therapeutics (NASDAQ: KTRA) announced that its President and CEO, Saiid Zarrabian, will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available on-demand from 7:00 A.M. ET on March 9 for 90 days. Kintara focuses on developing new therapies for solid tumors, currently advancing VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. VAL-083 has shown clinical activity in various cancers, while REM-001 has an 80% complete response rate in previous trials.

Kintara Therapeutics (Nasdaq: KTRA) has completed enrollment of the last patient in the recurrent arm of its Phase 2 clinical study for VAL-083, targeting glioblastoma multiforme (GBM). This trial, conducted at MD Anderson, involves 83 patients and aims to assess the efficacy of VAL-083 compared to standard treatments. The company plans to report topline results in Q2 2021. VAL-083 has shown promising median overall survival rates of 7.6 months in the recurrent group, with the drug granted Orphan Drug and Fast Track designations by the FDA.

Kintara Therapeutics (KTRA) reported its fiscal Q2 2021 results, highlighting significant advancements in its VAL-083 therapy for glioblastoma. The company entered a definitive agreement with GCAR to include VAL-083 in the GBM AGILE trial, with patient recruitment underway. Financially, Kintara showed a net loss of $5.4 million, or $0.22 per share, compared to a loss of $1.7 million in Q2 2020. Cash equivalents stood at $17.2 million, sufficient to fund operations into Q4 2021. The increased losses primarily resulted from non-cash expenses related to research and development acquisitions.